论文部分内容阅读
目的:探讨急性白血病患者多药耐药基因(mdr1)和DNA拓扑异构酶Ⅱ(TopoⅡ)的表达及其临床意义。方法:采用反转录—聚合酶链反应(RT-PCR)技术检测了52例急性白血病患者mdr1基因和DNA拓扑异构酶Ⅱ的表达。结果:复发难治组白血病患者mdr1阳性率83.3 %,明显高于初治组36.7 %和完全缓解组10.0 %。复发难治组TopoⅡ表达阳性率25.0 %,低于初治组43.3 %和完全缓解组70.0 %。mdr1和TopoⅡ二者表达之间无相关性(P>0.05)。mdr1(+)/TopoⅡ(-)者预后最差。结论: mdr1阳性和TopoⅡ的表达降低均是判断疗效和预后的重要指标。mdr1和TopoⅡ之间无相关性。
Objective: To investigate the expression of multidrug resistance gene (mdr1) and topoisomerase Ⅱ (Topo Ⅱ) in patients with acute leukemia and its clinical significance. Methods: The expression of mdr1 gene and DNA topoisomerase Ⅱ in 52 patients with acute leukemia were detected by reverse transcription-polymerase chain reaction (RT-PCR). Results: The positive rate of mdr1 in patients with relapsed and refractory leukemia was 83.3%, significantly higher than 36.7% in initial treatment group and 10.0% in complete remission group. The positive expression rate of TopoⅡ in relapsed and refractory group was 25.0%, which was lower than 43.3% in initial treatment group and 70.0% in complete remission group. There was no correlation between mdr1 and Topo Ⅱ expression (P> 0.05). mdr1 (+) / Topo Ⅱ (-) the worst prognosis. Conclusion: Both mdr1 positive and Topo Ⅱ expression decrease are important indicators to judge the curative effect and prognosis. No correlation between mdr1 and Topo II.